Ask AI
ProCE Banner Activity

Patient Resource: Understanding Treatment Options in MCL

PDF

Downloadable PDF resource as a helpful guide for patients in understanding treatment options for newly diagnosed or previously treated MCL.

Released: May 29, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan BTK inhibitor-based combination strategies for patients with treatment-naïve MCL, considering new indications, expert recommendations, and available efficacy and safety evidence

  • Select chemotherapy-free treatment strategies for appropriate patients with MCL

  • Manage treatment-related adverse events associated with targeted therapies alone or in combination to extend duration on treatment and improve clinical outcomes

Disclosure

Primary Author

Maria Gomes da Silva, MD, PhD: consultant/advisor/speaker: Janssen, Roche; other financial or material support: AbbVie, BeOne, Gilead, Janssen, Lilly; researcher: AstraZeneca.

George Hess, MD: consultant: AbbVie, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Gilead/Kite, Incyte, Janssen, Miltenyi, Merck Sharp & Dohme, Pierre Fabre, Regeneron, Roche, Sobi; researcher (paid to institution): AbbVie, Gilead/Kite, Janssen, Lilly, Roche; other financial or material support: AbbVie, ADC, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead/Kite, Incyte, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Sobi.

Mats Jerkeman, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Kite, Lilly, Sobi.

Ana Marin-Niebla, MD, PhD: consultant/advisor/speaker: AstraZeneca, BeOne, Johnson & Johnson, Lilly.

Carlo Visco, MD, has no relevant financial relationships to disclose.